Emerging GLP-1 receptor agonists

Sep 13, 2011Expert opinion on emerging drugs

New Developments in Drugs That Activate GLP-1 Receptors

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

GLP-1 receptor agonists are associated with sustained weight loss and improved glycemic control in type 2 diabetes.

Currently available GLP-1 receptor agonists include exenatide and liraglutide.
Emerging long-acting GLP-1 receptor agonists may enhance the benefits of existing therapies with fewer side effects.
Initial combination therapy with metformin and incretin-based therapies is anticipated for type 2 diabetes patients.
Meta-analyses indicate promising effects of GLP-1 receptor agonists on cardiovascular disease.
Data from ongoing multicenter trials with cardiovascular endpoints are expected in 2015.

AI simplified

INTRODUCTION: Recently, glucagon-like peptide-1 receptor (GLP-1R) agonists have become available for the treatment of type 2 diabetes. These agents exploit the physiological effects of GLP-1, which is able to address several of the pathophysiological features of type 2 diabetes. GLP-1R agonists presently available are administered once or twice daily, but several once-weekly GLP-1R agonists are in late clinical development.

AREAS COVERED: The present review aims to give an overview of the clinical data on the currently available GLP-1R agonists used for treatment of type 2 diabetes, exenatide and liraglutide, as well as the emerging GLP-1R agonists including the long-acting compounds.

EXPERT OPINION: An emerging therapeutic trend toward initial or early combination therapy with metformin- and incretin-based therapy is anticipated for patients with type 2 diabetes. GLP-1-based therapy has so far proven safe and tolerable. The determination of which incretin-based therapy to choose necessitates comparisons between the various GLP-1R agonists. The available GLP-1R agonists cause sustained weight loss and clinical relevant improvement of glycemic control. The long-acting GLP-1R agonists in late development may improve the effects of GLP-1 even further with optimized pharmacokinetic profiles resulting in fewer side effects. Meta-analyses have shown promising effects on cardiovascular disease and data from ongoing multicenter trials with cardiovascular endpoints are expected in 2015.

Full Text

Full text is available at the source.

View full text ↗

Emerging GLP-1 receptor agonists

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief